Biotech ETFs Feeling the Winds of Change

The biotechnology sector is about to see some major shifts as patents expire and M&A activity gathers steam. Exchange-traded funds (ETFs) are one of the best ways to get exposure to this dynamic and unpredictable sector.

Speculating on biotech mergers and acquisitions is about as solid a strategy as playing roulette, says John Jannarone for The Wall Street Journal. In other words, the house always wins. [5 Biotech ETFs for the Bullish.]

After a mixed start to the year, biotech ETFs might begin to see their fortunes change:

  • Generic Boost. The FDA has approved Novartis' (NYSE: NVS  ) generic version of the blood thinner Lovenox, says MediaPost. As pantented drugs expire, this could become a new source of revenue for the sector. Biologic medicine alone could become a $100 billion industry.
  • M&A Activity. A takeover by Sanofi-Aventis (NYSE: SNY  ) SA of biotech company Genzyme Corp. (Nasdaq: GENZ  ) is rumored to be in progress, according to Reuters. Sources familiar with the matter told Reuters on Friday that Sanofi-Aventis is searching for a large acquisition, lifting shares 15% on the news.
  • New Research. Joe Patterson for The Lipman Capital Times reports that a lab made up of modern biochemists is looking at the possibility that algae can be used as a biofuel in the future. Biotechnology can figure out a way to create an algae that converts sunlight into lipids and oils as fast as possible, then they will have created a new source of diesel and jet blue that can be harnessed.

Harnessing these changes through ETFs can lower the risk that often comes with single company exposure, due to the hit-or-miss nature of the sector and the smaller company size common in the industry. [First Trust Biotech ETF Makes It to the Top.]

For more stories about biotech, visit our biotech category. Our ETF Analyzer shows that there are currently five biotech ETFs trading now, including these three:

  • iShares Nasdaq Biotechnology ETF (Nasdaq: IBB  )
  • SPDR S&P Biotech ETF (NYSE: XBI  )
  • First Trust NYSE Arca Biotech ETF (NYSE: FBT  )

More from ETFTrends:

Novartis AG is a Motley Fool Global Gains selection. Try any of our Foolish newsletters today, free for 30 days. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1248259, ~/Articles/ArticleHandler.aspx, 11/28/2014 12:09:33 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement